Immune Thrombocytopenia in a Kidney Transplant Recipient Treated with Romiplostim

Melissa R. Laub, Muhammad Irfan Saeed, Rajan Kapoor, Allan Krutchik, Imran Gani

Research output: Contribution to journalReview articlepeer-review


We present a case of immune thrombocytopenia following a living donor kidney transplant. Thrombocytopenia started two days after transplant and continued up to seven weeks after transplant, despite an extensive workup, treatment with steroids, intravenous immune globulin, and alterations in immunosuppression and other medications. In the absence of platelet transfusions, the patient's platelet count remained < 20,000/mm3. Platelet count responded to romiplistim (Nplate®, Amgen Inc.) within two weeks and has remained stable for twelve months after initiation of this agent. The patient's graft function has also been stable. This experience suggests romiplostim is safe and effective for persistent immune thrombocytopenia in kidney transplant recipients.

Original languageEnglish (US)
Pages (from-to)69-74
Number of pages6
JournalAmerican Journal of the Medical Sciences
Issue number1
StatePublished - Jan 2022


  • Kidney transplantation
  • Thrombocytopenia
  • Thrombopoietin receptor agonists

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Immune Thrombocytopenia in a Kidney Transplant Recipient Treated with Romiplostim'. Together they form a unique fingerprint.

Cite this